2017 marks 20 years of Science and Service® provided by Cambridge Biomedical. We celebrate 20 years of supporting patients and those who help them. Please visit our updated website to appreciate our new logo that was commissioned to signify this important milestone.
Donor stem cell–derived retinal epithelial cells whose immune proteins correspond to those of a recipient are tolerated following transplant into monkeys’ eyes, according to a report published today (September 15) in Stem Cell Reports. In an accompanying paper, the team also reports that such immune-matched retinal cells derived from humans prevent immune responses in cultured human lymphocytes.
Cambridge Biomedical frequently works with clients on the optimum methodology for the collection of clinical samples. For many clinical trials this involves collection sites situated in different countries with varying levels of expertise and understanding of the correct processes to follow.
One of the critical areas we investigate when we develop an assay for a client, is the sample collection process and particularly the stability of the sample. For example, assays may involve the collection of PBMC’s, if these are not processed, correctly, within 24 hours of collection then the resulting data obtained from the assay can be seriously affected.
We identified this issue several years ago and introduced a video service for our clients. These videos are specifically tailored to the study requirements and detail the complete process,from venipuncture through to sample shipment.
The result of using these training videos has been a resounding success and we have seen a dramatic decrease in the quality of the resulting data.
If you would like to learn more about how Cambridge Biomedical can help with your sample collection process and bioanalytical analysis please visit our website and we will be delighted to assist.
We will be exhibiting at the AAPS National Biotechnology Conference being held at the Hynes Convention Center May 16-17 in our home city of Boston. If you are attending please come and see us at Booth # 103.
Dr Ralf Geiben Lynn, Senior Research Scientist at Cambridge biomedical has authored our latest whitepaper on the Development of novel Fluorescence-activated cell sorting (FACS) and Immunoprecipitation (IP)/Western-Blot assays to characterize antibody therapies.
Biotech industry is in a boom, and we at Cambridge Biomedical are proud that we can contribute to it. The arrival of new antibody therapies feels like a fresh ocean breeze at Biarritz, France, which we can still feel here in Boston. In our role as a bioanalytical assay CRO, we are involved in the development of novel therapeutic antibodies that show examples of how the industry creates sustainable growth, which drive this boom.
There are multiple new antibodies that boost the immune system and that are part of novel therapeutic interventions. Some of these antibodies enhance T-cell immune responses: Pembrolizumab (Keytruda, MK-3475, Merck) is approved to treat metastatic melanoma. New applications may include lung cancer and mesothelioma. Nivolumab (Opdivo, Bristol Myer Squibb) reduced non-small cell lung cancer, melanoma, renal-cell cancer in a clinical trial. Pidilizumab (CT-OII, Cure Tech) MPDL328OA (Roche) and BMS936559 (Bristol Myers Squibb) are also tested for other novel applications.